OTCM OTC Markets Group Cl A

HLS Therapeutics to Webcast Live at Life Sciences Investor Forum December 17th

HLS Therapeutics to Webcast Live at Life Sciences Investor Forum December 17th

Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on LifeSciencesInvestorForum.com

TORONTO, Dec. 14, 2020 (GLOBE NEWSWIRE) -- HLS Therapeutics Inc. (“HLS” or the “Company”) (TSX:HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, today announced that Gilbert Godin, CEO, will present live at LifeSciencesInvestorForum.com on December 17th.

DATE: Thursday, December 17th

TIME: 11:30 AM ET

LINK:

This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.

It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates.

Learn more about the event at .

About HLS Therapeutics Inc.

Formed in 2015, HLS is a specialty pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS’s focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS’s management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information, please visit:

About Life Sciences Investor Forum

Life Sciences Investor Forum is the leading proprietary investor conference series that provides an interactive forum for Life Sciences companies to meet with and present directly to investors.

A real-time solution for investor engagement, Life Sciences Investor Forum is powered by Intrado Digital Media and specifically designed for more efficient investor access. Replicating the look and feel of on-site investor conferences, Life Sciences Investor Forum combines leading-edge conferencing and investor communications capabilities with a comprehensive global investor audience network.



HLS Contact:
Dave Mason
Investor Relations
HLS Therapeutics Inc.
(416) 247-9652
 

Life Sciences Investor Forum
John M. Viglotti
SVP Corporate Services, Investor Access
(212) 220-2221
 
EN
14/12/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OTC Markets Group Cl A

 PRESS RELEASE

OTC Markets Group Welcomes First Phosphate Corp. to OTCQX

OTC Markets Group Welcomes First Phosphate Corp. to OTCQX NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced (CSE: PHOS; OTCQX: FRSPF), an igneous phosphate mineral development company for the LFP battery industry, has qualified to trade on the OTCQX® Best Market. First Phosphate Corp. upgraded to OTCQX from the OTCQB® Venture Market. First Phosphate Corp. begins trading today on OTCQX under the symbol “FRSPF.” U.S. investors can find current financial disclosure and Real-Time ...

 PRESS RELEASE

OTC Markets Group Welcomes Limitless X Holdings Inc. to OTCQX

OTC Markets Group Welcomes Limitless X Holdings Inc. to OTCQX NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced (OTCQX: LIMX), a company that specializes in direct-to-consumer eCommerce, has qualified to trade on the OTCQX® Best Market. Limitless X Holdings Inc. upgraded to OTCQX from the OTCQB® Venture Market. Limitless X Holdings Inc. begins trading today on OTCQX under the symbol “LIMX.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for...

 PRESS RELEASE

OTC Markets Group Reports Second Quarter 2025 Financial Results Delive...

OTC Markets Group Reports Second Quarter 2025 Financial Results Delivering Revenue, Operating Income, and Earnings Growth Second Quarter 2025 Highlights: Gross revenues of $30.5 million for the quarter, up 11% versus the prior year periodOperating income of $8.8 million for the quarter, up 8% versus the prior year periodOperating profit margin of 29.9%, versus 30.4% for the prior year periodNet income of $7.3 million, up 8% versus the prior year period, and quarterly diluted GAAP EPS of $0.60, up 7% Total cash returned to shareholders during the quarter of $2.2 million, in the form of divi...

 PRESS RELEASE

OTC Markets Group Welcomes Alkane Resources Limited to OTCQX

OTC Markets Group Welcomes Alkane Resources Limited to OTCQX NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) -- (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced (ASX: ALK; OTCQX: ALKEF), a diversified Australia-based gold and antimony producer, has qualified to trade on the OTCQX® Best Market. Alkane Resources Limited upgraded to OTCQX from the Pink® market. Alkane Resources Limited begins trading today on OTCQX under the symbol “ALKEF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for t...

 PRESS RELEASE

OTC Markets Group Announces Quarterly Index Performance and Rebalancin...

OTC Markets Group Announces Quarterly Index Performance and Rebalancing NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- (OTCQX: OTCM), operator of regulated financial markets for trading 12,000 U.S. and global securities, today announced the second quarter 2025 performance and quarterly rebalancing of the OTCQX® indexes, including the OTCQX Canada Index and the OTCQX Dividend Index. The OTCQX Composite Index (.OTCQX), a benchmark for the overall OTCQX Best Market, was up 10.3% in Q2 2025. 43 new companies joined the Index while 40 companies were removed. Dolly Varden Silver Corporation (DVS...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch